New Zealand markets close in 5 hours 47 minutes

Ocular Therapeutix, Inc. (OCUL)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
5.63-0.03 (-0.53%)
At close: 04:00PM EST
5.63 0.00 (0.00%)
After hours: 04:14PM EST

Ocular Therapeutix, Inc.

24 Crosby Drive
Bedford, MA 01730
United States
781 357 4000
https://www.ocutx.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees181

Key executives

NameTitlePayExercisedYear born
Mr. Antony MattessichPres, CEO & Director1.03MN/A1967
Mr. Philip C. StrassburgerGen. Counsel282.61kN/A1960
Dr. Michael H. Goldstein M.M., M.D., M.B.A.Pres of Ophthalmology & Chief Medical Officer661.15kN/A1967
Mr. Donald Notman Jr.Chief Financial OfficerN/AN/AN/A
Dr. Peter K. Jarrett Ph.D.Chief Scientific OfficerN/AN/A1957
Mr. William H. Ransone IIVP of Global Sales & MarketingN/AN/AN/A
Ms. Tracy SmithVP of HRN/AN/AN/A
Mr. Scott CorningSr. VP of CommercialN/AN/AN/A
Mr. Christopher G. WhiteChief Bus. OfficerN/AN/A1962
Dr. Rabia Gurses OzdenSr. VP of Clinical Devel.N/AN/A1969
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. The company markets ReSure Sealant, an ophthalmic device designed to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant administered by the fine-gauge needle that is in phase 1 clinical trial for the treatment of wet age-related macular degeneration; OTX-TIC, a travoprost intracameral implant, which is in phase 1 clinical trial for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that is in phase 2 clinical trial for the chronic treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trial for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company is involved in the development of OTX-AFS, an aflibercept suprachoroidal injection for the treatment of retinal diseases. It has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of Dry Age-related Macular Degeneration. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Corporate governance

Ocular Therapeutix, Inc.’s ISS governance QualityScore as of 26 September 2021 is 9. The pillar scores are Audit: 9; Board: 9; Shareholder rights: 7; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.